Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.47), $0.01 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Lumentum shares rise on analyst upgrades, AI demand outlook